PCRC_A021501

Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with or without hypofractionated radiation therapy before surgery works in patients with pancreatic cancer that can be removed by surgery. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. It is not yet known if combination chemotherapy is more effective with or without hypofractionated radiation therapy before surgery in treating patients with pancreatic cancer.

Key Eligibility:
•Confirmation of radiographic stage as borderline resectable disease by real-time Alliance central radiographic review
•No prior chemotherapy or radiation for pancreatic cancer
•No definitive resection of pancreatic cancer
•No grade greater than or equal to 2 neuropathy
•No uncontrolled gastric ulcer disease (grade 3 gastric ulcer disease) within 28 days of registration
Phase II
NCT02839343
Cancer
Gastrointestinal
Alison Conlin, M.D.
Alliance
Mary Mccormick

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.